Eli Lilly and Company and Hims & Hers Health, Inc. announced an agreement on November 6, 2026, to make Zepbound (tirzepatide) and Foundayo (orforglipron) available to eligible patients through the Hims & Hers platform at self-pay prices starting at $149 and $299 per month respectively.

Key Highlights

  • Two medicines covered: The agreement covers Zepbound (tirzepatide) and Foundayo (orforglipron), both FDA-approved Lilly obesity treatments.
  • Self-pay pricing: According to the announcement, self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound.
  • Patient experience: Eligible patients can complete a consultation, receive a prescription, and have medication shipped directly to their home without leaving the Hims & Hers platform, the companies disclosed.
  • No compounded copies: The filing states that Hims & Hers has never offered access to compounded copies of Lilly's GLP-1s and has committed not to do so in the future.
  • Clinical independence protected: As part of the agreement, both companies committed to protecting independent clinical decision-making by providers on the Hims & Hers platform.
  • Membership benefits: Weight loss patients on Hims & Hers receive 24/7 care team access, nutrition guidance, regular clinical check-ins, and access to the Hims & Hers Weight Loss community, according to the filing.

Lilly and Hims & Hers Partnership: Terms and Patient Access Details

Eli Lilly and Company (NYSE:LLY) and Hims & Hers Health, Inc. (NYSE:HIMS) disclosed an agreement on November 6, 2026, designed to expand patient access to two of Lilly's obesity medicines through the Hims & Hers digital health platform. According to the filing, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient, with Foundayo priced starting at $149 per month and Zepbound starting at $299 per month.

The filing describes the arrangement as bringing together Lilly's obesity medicine portfolio and Hims & Hers' consumer technology platform. Patients can complete a consultation, receive a prescription if the provider determines it is appropriate, and have an FDA-approved Lilly medicine shipped directly to their home, all within the Hims & Hers platform. Ilya Yuffa, Executive Vice President and President of Lilly USA and Global Customer Capabilities, was quoted in the filing stating: "Millions of people turn to Hims & Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed."

The filing also notes that Hims & Hers has never offered access to compounded copies of Lilly's GLP-1s and has committed not to do so in the future. Both companies additionally committed to protecting independent clinical decision-making, so that providers on the Hims & Hers platform continue to prescribe the treatment they determine is appropriate for each patient. Andrew Dudum, co-founder and CEO of Hims & Hers, was quoted in the filing expressing support for the arrangement, noting it is intended to reach "more people with obesity with seamless, personal access to FDA-approved Lilly medicine."

What Was Disclosed

Eli Lilly and Hims & Hers announced a commercial agreement on November 6, 2026, covering patient access to Zepbound and Foundayo through the Hims & Hers platform at defined self-pay prices, with commitments on compounded copies and clinical independence.